Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 26, 2024; 12(18): 3555-3560
Published online Jun 26, 2024. doi: 10.12998/wjcc.v12.i18.3555
Cytokine release syndrome triggered by programmed death 1 blockade (sintilimab) therapy in a psoriasis patient: A case report
Ming-Hui Zhou, Min-Feng Ye, Zhen-Xing Zhang, Feng Tao, Yu Zhang
Ming-Hui Zhou, Min-Feng Ye, Zhen-Xing Zhang, Feng Tao, Yu Zhang, Department of Gastrointestinal Surgery, Shaoxing People’s Hospital, Shaoxing 312000, Zhejiang Province, China
Ming-Hui Zhou, School of Medicine, Shaoxing University, Shaoxing 312000, Zhejiang Province, China
Author contributions: Zhou MH and Ye MF contributed to manuscript writing and editing and data collection; Zhang ZX and Tao F contributed to data analysis; Zhang Y contributed to conceptualization and supervision; and all authors have read and approved the final manuscript.
Supported by Shaoxing Health Science and Technology Program, No. 2022SY016 and No. 2022KY010.
Informed consent statement: Informed consent of the patient for publication, including personal data and pictures.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read CARE Checklist (2016), and the manuscript was prepared and revised according to CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu Zhang, MM, Surgeon, Department of Gastrointestinal Surgery, Shaoxing People’s Hospital, No. 568 Zhongxing North Road, Shaoxing 312000, Zhejiang Province, China. zhangyu9779@yeah.net
Received: January 22, 2024
Revised: April 10, 2024
Accepted: May 8, 2024
Published online: June 26, 2024
Processing time: 147 Days and 19.9 Hours
Abstract
BACKGROUND

In recent years, immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy across diverse malignancies. Notably, in patients with advanced gastric cancer, the use of programmed death 1 (PD-1) blockade has significantly prolonged overall survival, marking a pivotal advancement comparable to the impact of Herceptin over the past two decades. While the therapeutic benefits of ICIs are evident, the increasing use of immunotherapy has led to an increase in immune-related adverse events.

CASE SUMMARY

This article presents the case of a patient with advanced gastric cancer and chronic plaque psoriasis. Following sintilimab therapy, the patient developed severe rashes accompanied by cytokine release syndrome (CRS). Fortunately, effective management was achieved through the administration of glucocorticoid, tocilizumab, and acitretin, which resulted in favorable outcomes.

CONCLUSION

Glucocorticoid and tocilizumab therapy was effective in managing CRS after PD-1 blockade therapy for gastric cancer in a patient with chronic plaque psoriasis.

Keywords: Cytokine release syndrome; Programmed death 1 blockade; Sintilimab; Psoriasis; Gastric cancer; Case report

Core Tip: The increasing use of immunotherapy has led to an increase in immune-related adverse events. This article presents the case of a patient with advanced gastric cancer and chronic plaque psoriasis. Following sintilimab therapy, the patient developed severe rashes accompanied by cytokine release syndrome. Fortunately, effective management was achieved through the administration of glucocorticoids, tocilizumab, and acitretin, which resulted in favorable treatment outcomes.